Acrivon Therapeutics Q3 net loss narrows to $18.2 mln

Reuters11-14

Acrivon <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 net loss narrows to $18.2 mln

Overview

Acrivon Q3 net loss narrows to $18.2 mln from $22.4 mln last year
Research and development expenses fell due to fewer milestones and focus on endometrial cancer
Company has $134.4 mln in cash, funding operations into Q2 2027

Outlook

Company expects cash to fund operations into Q2 2027

Result Drivers

Research and development expenses were $13.6 million for the quarter ended September 30, 2025, compared to $18.9 million for the same period in 2024.

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$18.23 mln
Q3 Basic EPS		-$0.47
Q3 Income From Operations		-$19.69 mln
Q3 Operating Expenses		$19.69 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Acrivon Therapeutics Inc is $10.50, about 78.3% above its November 12 closing price of $2.28

Press Release: ID:nGNX76MHbB

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583512977?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 05:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583512977","market":"nz","top_or_hot":-1,"title":"Acrivon Therapeutics Q3 net loss narrows to $18.2 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Acrivon <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss narrows to $18.2 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Acrivon Q3 net loss narrows to $18.2 mln from $22.4 mln last year</p></li><li><p>Research and development expenses fell due to fewer milestones and focus on endometrial cancer</p></li><li><p>Company has $134.4 mln in cash, funding operations into <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash to fund operations into Q2 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses were $13.6 million for the quarter ended September 30, 2025, compared to $18.9 million for the same period in 2024.</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.23 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.47</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$19.69 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$19.69 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Acrivon Therapeutics Inc is $10.50, about 78.3% above its November 12 closing price of $2.28</p></li></ul><p>Press Release: <span>ID:nGNX76MHbB</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acrivon Therapeutics Q3 net loss narrows to $18.2 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcrivon Therapeutics Q3 net loss narrows to $18.2 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 05:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Acrivon <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 net loss narrows to $18.2 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Acrivon Q3 net loss narrows to $18.2 mln from $22.4 mln last year</p></li><li><p>Research and development expenses fell due to fewer milestones and focus on endometrial cancer</p></li><li><p>Company has $134.4 mln in cash, funding operations into <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2027</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash to fund operations into Q2 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses were $13.6 million for the quarter ended September 30, 2025, compared to $18.9 million for the same period in 2024.</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.23 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.47</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$19.69 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$19.69 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Acrivon Therapeutics Inc is $10.50, about 78.3% above its November 12 closing price of $2.28</p></li></ul><p>Press Release: <span>ID:nGNX76MHbB</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP194:1","article_id":"2583512977","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583512977","pubTimestamp":1763069313,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Acrivon Therapeutics Q3 net loss narrows to $18.2 mlnOverviewAcrivon Q3 net loss narrows to $18.2 mln from $22.4 mln last yearResearch and development expenses fell due to fewer milestones and focus o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ACRV":"Acrivon Therapeutics, Inc."},"translate_title":"Acrivon Therapeutics第三季度净亏损收窄至1820万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACRV":0.9},"content_text":"Acrivon Therapeutics Q3 net loss narrows to $18.2 mlnOverviewAcrivon Q3 net loss narrows to $18.2 mln from $22.4 mln last yearResearch and development expenses fell due to fewer milestones and focus on endometrial cancerCompany has $134.4 mln in cash, funding operations into Q2 2027OutlookCompany expects cash to fund operations into Q2 2027Result DriversResearch and development expenses were $13.6 million for the quarter ended September 30, 2025, compared to $18.9 million for the same period in 2024.Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$18.23 mlnQ3 Basic EPS-$0.47Q3 Income From Operations-$19.69 mlnQ3 Operating Expenses$19.69 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Acrivon Therapeutics Inc is $10.50, about 78.3% above its November 12 closing price of $2.28Press Release: ID:nGNX76MHbBFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583512977","isCrawlerRequest":true}